Bristol Myers' combo hits a roadblock in PhIII kidney test as the search to rival Keytruda continues
Bristol Myers Squibb has hit a snag in its Phase III trial investigating the company’s Opdivo and Yervoy combo in renal cell carcinoma, or RCC.
Researchers had been investigating Opdivo and Yervoy together as a potential treatment for patients who have undergone a full or partial removal of their kidney and who are at a higher risk of a relapse. But in a release Friday, part A of its Phase III study, dubbed CheckMate -914, “did not meet the primary endpoint of disease-free survival,” the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.